Avastin Causing Gastrointestinal Perforations, New Ovarian Cancer Trial Enrollments Suspended By Genentech Inc
Featured ArticleMain Category: Ovarian Cancer
Article Date: 23 Sep 2005 - 19:00 PDT
email to a friend 
printer friendly 
opinions
| Patient / Public: |  |
3 (2 votes) |
| Healthcare Prof: |  |
Genentech Inc decided not to enrol any more volunteers into its study of Avastin for the treatment of ovarian cancer because more people than they had expected had experienced gastrointestinal perforations - the suspension happened after the company met with the FDA.
Our of 44 patients on the trial, five had gastrointestinal perforations. Gastrointestinal perforation is a possible side effect of using this drug. However, Genentech said the number of people experiencing this side effect was higher than they had expected.
Genentech had hoped for 53 trial participants. Those who are already in the trial can decide for themselves whether they want to carry on, or not.
Avasting is currently used for the treatment of advanced colon cancer. Researchers at Genentech are hoping it may prove effective in the treatment of other cancers, such as kidney, prostate, pancreas and ovary.
Genentech Inc.
Written by: Christian Nordqvist
Editor - Medical News Today
Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today
MLA
15 Feb. 2012. <http://www.medicalnewstoday.com/articles/31081.php>
APA
http://www.medicalnewstoday.com/articles/31081.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
Privacy Policy |
Terms and Conditions
MediLexicon International Ltd
Bexhill-on-Sea, United Kingdom
MediLexicon International Ltd © 2004-2012 All rights reserved.
